The Global ENT Treatment Market Size accounted for USD 21.1 Billion in 2021 and is estimated to garner a market size of USD 33.9 Billion by 2030 rising at a CAGR of 5.5% from 2022 to 2030. Increasing air and noise pollution is one of the significant factors that drive the ear, nose, and throat (ENT) market growth. The ENT disorder treatment is very common in the world today and it can cause severe healthcare issues for all age groups. The rising elderly population is another factor that is supporting the global ENT disorder treatment industry. Furthermore, growing R&D to discover new treatment methods for these patients is a very popular ENT treatment market trend that will fuel the demand in the coming years.
ENT Treatment Market Report Key Highlights
- Global ENT treatment market revenue is estimated to reach USD 33.9 Billion by 2030 with a CAGR of 5.5% from 2022 to 2030
- North America ENT treatment market share accounted for over 37% regional shares in 2021
- According to the CDC statistics, around 30% of all hearing loss cases in Europe are due to noise pollution
- Asia-Pacific ENT treatment market growth will record fastest CAGR from 2022 to 2030
- Based on organ type segment, Nose accounted for approx 50% of the overall market share in 2021
- Rising prevalence of anti-bacterial resistance propels the ear, nose, and throat (ENT) treatment market value in coming years
An increase in the number of patients suffering from ENT problems across the globe, rapid advancements in the development of advanced treatment, and a rise in awareness among consumers related to the availability of minimally invasive surgical procedures are major factors expected to drive the growth of global ear, nose, and throat treatment market. According to the World Health Organization (WHO), nearly 2.5 billion people across the globe, or one in every four, will have some degree of hearing loss by 2050. Centers for Disease Control and Prevention states that: out of every 1,000 children, about 2 to 3 are born with hearing loss in both ears in the US. In addition, approximately 15% of American adults (37.5 million) aged 18 and over report some trouble hearing. Tonsillitis, sinus infections, and ear infections are some of the major ENT problems witnessed by doctors every year. According to Getting It Right First Time (GIRFT), UK statistics, 330,000 patients were admitted to hospitals with ENT disorders. Also, tonsillectomy accounts for 17% of the total elective workload, with 2.8 million outpatient visits. Consumer spending on healthcare is increasing and with the availability of advanced healthcare infrastructure their approach towards the availability of better care to patients is increasing.
Global ENT Treatment Market Dynamics
Market Drivers
- Growing air and noise pollution
- Rising development of antibiotics
- Surging minimally invasive procedures
- Rapid innovation in development of advanced treatment
Market Restraints
- High cost of medical devices and drugs for tonsillitis and sinusitis
- Lack of awareness in emerging economies
Market Opportunities
- Increasing penetration of robotics in ENT treatment procedures
- Surplus investments in healthcare infrastructure
ENT Treatment Market Report Coverage
Market |
ENT Treatment Market |
ENT Treatment Market Size 2021 |
USD 21.1 Billion |
ENT Treatment Market Forecast 2030 |
USD 33.9 Billion |
ENT Treatment Market CAGR During 2022 - 2030 |
5.5% |
ENT Treatment Market Analysis Period |
2018 - 2030 |
ENT Treatment Market Base Year |
2021 |
ENT Treatment Market Forecast Data |
2022 - 2030 |
Segments Covered |
By Organ Type, By Treatment Type, By End-User, And By Geography
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Key Companies Profiled |
Medtronic plc, Cochlear Limited, Sanofi, Pfizer Inc., Merck & Co., Inc., Johnson and Johnson Olympus Corporation, Smith & Nephew plc, Siemens Healthcare GmbH, Starkey Laboratories, Inc, and Demant A/S. |
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
ENT Treatment Market Dynamics
The rise in the geriatric population in developing countries and the increase in problems associated with hearing among them is expected to increase demand for minimally invasive devices and treatment procedures. In addition, increasing penetration of robotics in treatment procedures in order to deliver high precision in the diagnosis of diseases are some factors expected to boost the ear, nose, and throat (ENT) treatment market growth. The government is spending high on the development of present infrastructure with a focus to deliver enhanced care to the patients and aiding enterprises in R&D activities. For instance, NHS spends approximately US$ 37.5 million on ENT products and technologies among which cochlear implants, bone-anchored hearing aids (BAHAs), processors, and accessories account for 80% of these expenditures. The government is providing better reimbursement policies to consumers in order to facilitate healthcare treatment. For example:
- The UK provides complete free healthcare in some parts of the country. If the person/patient is S2 approved then the UK government will be solely in charge of the patient's care. The 100% cost of patient treatment would be covered by the government.
- European Health Insurance Card (EHIC), is a healthcare service for (European Economic Area) EEA countries where it covers all the costs of patients in any unplanned medical situation with state-funded treatment. EHIC will reimburse the cost of treatment.
ENT Treatment Market Segmentation
The worldwide ENT treatment market is split based on organ type, treatment type, end-user, and geography.
ENT Treatment Market By Organ Type
According to our ENT treatment industry analysis, the nose organ accumulated a significant market share in 2021. Additionally, the ear segment is expected to attain a substantial growth rate in the coming years. This is attributed to raise in number of ear infection cases across the globe. Increasing R&D activities by major players and introduction of innovative devices is expected to support the segment growth.
ENT Treatment Market By Treatment Type
As per our ENT treatment market forecast, the drugs segment dominated the global ENT treatment market with noteworthy share from 2022 to 2030. However, the devices sub-segment would spur with a considerable growth rate during the forecasted timeframe. The rising innovation in developing new devices for diagnosis and treatment of ear, nose, and throat are likely to support the segment in the coming years.
ENT Treatment Market By End-User
- Hospitals
- Clinics
- Home Care Settings
- Others
Among end-users, the hospital's segment accounted for the highest ENT disorder treatment market share in 2021, due to increasing government spending on the development of hospital infrastructure and focus to deliver enhanced care to the patients. On the other hand, the home care settings are on a boom due to the advent of COVID-19 pandemic and the rising disposable income coupled with the highly aware population regarding the treatment if ear, nose, and throat (ENT).
ENT Treatment Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
The Middle East & Africa (MEA)
- Gulf Cooperation Council (GCC)
- South Africa
- Rest of the Middle East & Africa
In 2021, North America held the major share of the global ENT Treatment market
North America accounted for revenue of US$ 7.8 billion in 2021 and is expected to continue its dominance over the market due to the rising number of patients suffering from various ear and nose infections. The availability of favorable reimbursement policies by the government and the presence of advanced healthcare infrastructure are expected to impact the growth of ear, nose, and throat disorder treatment market. Consumer preference for home care is increasing; with the availability of developed infrastructure adoption of advanced devices is easy to provide patients better care. The presence of a large number of players operating in the country and the introduction of new solutions is expected to boost the ear, nose, and throat (ENT) treatment market growth. The government is providing favorable policies for product approvals. In 2019, the Food and Drug Administration (FDA), approved "Dupixent (dupilumab)" to treat adults with nasal polyps and chronic rhinosinusitis. This is the first treatment approved by the FDA for inadequately controlled chronic rhinosinusitis with nasal polyps.
ENT Treatment Market Players
The global ENT treatment companies profiled in the report include Medtronic plc, Cochlear Limited, Sanofi, Pfizer Inc., Merck & Co., Inc., Johnson and Johnson Olympus Corporation, Smith & Nephew plc, Siemens Healthcare GmbH, Starkey Laboratories, Inc, and Demant A/S.
CHAPTER 1. Industry Overview of ENT Treatment Market
1.1. Definition and Scope
1.1.1. Definition of ENT Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global ENT Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. ENT Treatment Market By Organ Type
1.2.3. ENT Treatment Market By Treatment Type
1.2.4. ENT Treatment Market By End-User
1.2.5. ENT Treatment Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of ENT Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for ENT Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. ENT Treatment Market By Organ Type
4.1. Introduction
4.2. ENT Treatment Revenue By Organ Type
4.2.1. ENT Treatment Revenue (USD Billion) and Forecast, By Organ Type, 2018-2030
4.2.2. Ears
4.2.2.1. Ears Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
4.2.3. Nose
4.2.3.1. Nose Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
4.2.4. Throat
4.2.4.1. Throat Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 5. ENT Treatment Market By End-User
5.1. Introduction
5.2. ENT Treatment Revenue By End-User
5.2.1. ENT Treatment Revenue (USD Billion) and Forecast, By End-User, 2018-2030
5.2.2. Hospitals
5.2.2.1. Hospitals Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.3. Clinics
5.2.3.1. Clinics Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.4. Home Care Settings
5.2.4.1. Home Care Settings Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.5. Others
5.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 6. North America ENT Treatment Market By Country
6.1. North America ENT Treatment Market Overview
6.2. U.S.
6.2.1. U.S. ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
6.2.2. U.S. ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
6.2.3. U.S. ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
6.3. Canada
6.3.1. Canada ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
6.3.2. Canada ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
6.3.3. Canada ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
6.4. North America PEST Analysis
CHAPTER 7. Europe ENT Treatment Market By Country
7.1. Europe ENT Treatment Market Overview
7.2. U.K.
7.2.1. U.K. ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
7.2.2. U.K. ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
7.2.3. U.K. ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
7.3. Germany
7.3.1. Germany ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
7.3.2. Germany ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
7.3.3. Germany ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
7.4. France
7.4.1. France ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
7.4.2. France ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
7.4.3. France ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
7.5. Spain
7.5.1. Spain ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
7.5.2. Spain ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
7.5.3. Spain ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
7.6. Rest of Europe
7.6.1. Rest of Europe ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
7.6.2. Rest of Europe ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
7.6.3. Rest of Europe ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
7.7. Europe PEST Analysis
CHAPTER 8. Asia Pacific ENT Treatment Market By Country
8.1. Asia Pacific ENT Treatment Market Overview
8.2. China
8.2.1. China ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
8.2.2. China ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
8.2.3. China ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.3. Japan
8.3.1. Japan ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
8.3.2. Japan ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
8.3.3. Japan ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.4. India
8.4.1. India ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
8.4.2. India ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
8.4.3. India ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.5. Australia
8.5.1. Australia ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
8.5.2. Australia ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
8.5.3. Australia ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.6. South Korea
8.6.1. South Korea ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
8.6.2. South Korea ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
8.6.3. South Korea ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
8.7.2. Rest of Asia-Pacific ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
8.7.3. Rest of Asia-Pacific ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
8.8. Asia Pacific PEST Analysis
CHAPTER 9. Latin America ENT Treatment Market By Country
9.1. Latin America ENT Treatment Market Overview
9.2. Brazil
9.2.1. Brazil ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
9.2.2. Brazil ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
9.2.3. Brazil ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.3. Mexico
9.3.1. Mexico ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
9.3.2. Mexico ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
9.3.3. Mexico ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.4. Rest of Latin America
9.4.1. Rest of Latin America ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
9.4.2. Rest of Latin America ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
9.4.3. Rest of Latin America ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
9.5. Latin America PEST Analysis
CHAPTER 10. Middle East & Africa ENT Treatment Market By Country
10.1. Middle East & Africa ENT Treatment Market Overview
10.2. GCC
10.2.1. GCC ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
10.2.2. GCC ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
10.2.3. GCC ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.3. South Africa
10.3.1. South Africa ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
10.3.2. South Africa ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
10.3.3. South Africa ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa ENT Treatment Revenue (USD Billion) and Forecast By Organ Type, 2018-2030
10.4.2. Rest of Middle East & Africa ENT Treatment Revenue (USD Billion) and Forecast By Treatment Type, 2018-2030
10.4.3. Rest of Middle East & Africa ENT Treatment Revenue (USD Billion) and Forecast By End-User, 2018-2030
10.5. Middle East & Africa PEST Analysis
CHAPTER 11. Player Analysis Of ENT Treatment Market
11.1. ENT Treatment Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global ENT Treatment Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 12. Company Profile
12.1. Medtronic plc
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (USD Billion), 2021
12.1.3.2. Medtronic plc 2021 ENT Treatment Business Regional Distribution
12.1.4. Product /Service and Specification
12.1.5. Recent Developments & Business Strategy
12.2. Cochlear Limited
12.3. Sanofi
12.4. Pfizer Inc.
12.5. Merck & Co., Inc.
12.6. Johnson and Johnson
12.7. Olympus Corporation
12.8. Smith & Nephew plc
12.9. Siemens Healthcare GmbH
12.10. Starkey Laboratories, Inc
12.11. Demant A/S